MoonLake Immunotherapeutics: Strong Acquisition Interest and Promising Product Pipeline Drive Buy Rating

Citi analyst Samantha Semenkow has maintained their bullish stance on MLTX stock, giving a Buy rating on May 27.

Samantha Semenkow’s rating is based on several compelling factors that make MoonLake Immunotherapeutics an attractive investment opportunity. One of the primary reasons is the potential acquisition interest from major pharmaceutical companies, such as Merck, which indicates a strong market confidence in MoonLake’s innovative treatments. Although a non-binding offer from Merck was reportedly rejected, the interest itself highlights the company’s value and potential for future growth.
Samantha also emphasizes the promising prospects of MoonLake’s lead product, sonelokimab, which is being developed for multiple indications including hidradenitis suppurativa and psoriatic arthritis. The upcoming Phase 3 data and potential launch in 2027 could significantly enhance the company’s market position. Additionally, the analyst notes that recent biotech acquisition premiums suggest a higher valuation potential for MoonLake, reinforcing the Buy rating with an expected share price return of 74.9%.

In another report released on May 27, H.C. Wainwright also reiterated a Buy rating on the stock with a $100.00 price target.

MLTX’s price has also changed moderately for the past six months – from $55.470 to $41.160, which is a -25.80% drop .